Literature DB >> 8704259

Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase.

H Kitayama1, T Tsujimura, I Matsumura, K Oritani, H Ikeda, J Ishikawa, M Okabe, M Suzuki, K Yamamura, Y Matsuzawa, Y Kitamura, Y Kanakura.   

Abstract

The c-kit proto-oncogene encodes a receptor tyrosine kinase that is crucial to hematopoiesis, melanogenesis, and gametogeneis. Although the enzymatic activity of the c-kit product (KIT) is regulated by its ligand, both the Val559-->Gly (G559) mutation in the juxtamembrane domain and the Asp814-->Val (V814) mutation in the phosphotransferase domain lead to constitutive activation of KIT. By retroviral infection of hematopoietic progenitor cells with KIT(G559) or KIT(V814), KIT(G559) induced development of granulocyte/macrophage and mast-cell colonies in vitro without the addition of exogenous growth factors. KIT(V814) induced factor-independent growth of various types of hematopoietic progenitor cells, resulting in the development of mixed erythroid/myeloid colonies in addition to granulocyte/macrophage and mast-cell colonies. Furthermore, transplantation of KIT(G559) and KIT(V814)-infected bone marrow cells led to development of acute leukemia in one of 10 and six of 10 transplanted mice, respectively. No mice developed hematologic malignancies after transplantation of wild-type KIT-infected cells. Furthermore, transgenic mice expressing KIT(V814) developed acute leukemia or malignant lymphoma. These results demonstrate a direct role of the mutant KITs, particularly KIT(V814), in tumorigenesis of hematopoietic cells and suggest that similar mutations may contribute to the development of human hematologic malignancies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8704259

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.

Authors:  Heidi J Nick; Hyung-Gyoon Kim; Chia-Wei Chang; Kevin W Harris; Vishnu Reddy; Christopher A Klug
Journal:  Blood       Date:  2011-09-21       Impact factor: 22.113

2.  RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group.

Authors:  Hirozumi Sano; Akira Shimada; Tomohiko Taki; Chisato Murata; Myoung-Ja Park; Manabu Sotomatsu; Ken Tabuchi; Akio Tawa; Ryoji Kobayashi; Keizo Horibe; Masahiro Tsuchida; Ryoji Hanada; Ichiro Tsukimoto; Yasuhide Hayashi
Journal:  Int J Hematol       Date:  2012-03-10       Impact factor: 2.490

3.  Activation of Wnt signaling in cKit-ITD mediated transformation and imatinib sensitivity in acute myeloid leukemia.

Authors:  Lara Tickenbrock; Sina Hehn; Bülent Sargin; Georg Evers; Pavankumar Reddy Ng; Chunaram Choudhary; Wolfgang E Berdel; Carsten Müller-Tidow; Hubert Serve
Journal:  Int J Hematol       Date:  2008-07-31       Impact factor: 2.490

Review 4.  Target validation to biomarker development: focus on RNA interference.

Authors:  Riccardo Colombo; Jürgen Moll
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

5.  Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling.

Authors:  Zhifu Xiang; Frederike Kreisel; Jennifer Cain; AnnaLynn Colson; Michael H Tomasson
Journal:  Mol Cell Biol       Date:  2006-10-23       Impact factor: 4.272

6.  Identification of a novel point mutation of mouse proto-oncogene c-kit through N-ethyl-N-nitrosourea mutagenesis.

Authors:  Hai-Bin Ruan; Nian Zhang; Xiang Gao
Journal:  Genetics       Date:  2005-02       Impact factor: 4.562

7.  Surgery for gastrointestinal stromal tumors of the stomach.

Authors:  Gerd R Silberhumer; Martin Hufschmid; Fritz Wrba; Georg Gyoeri; Sebastian Schoppmann; Barbara Tribl; Etienne Wenzl; Gerhard Prager; Friedrich Laengle; Johannes Zacherl
Journal:  J Gastrointest Surg       Date:  2009-04-09       Impact factor: 3.452

8.  Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.

Authors:  Veerendra Munugalavadla; Emily C Sims; Jovencio Borneo; Rebecca J Chan; Reuben Kapur
Journal:  Blood       Date:  2007-05-04       Impact factor: 22.113

9.  Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase.

Authors:  Gunhild Sommer; Valter Agosti; Imke Ehlers; Ferdinand Rossi; Selim Corbacioglu; Judith Farkas; Malcolm Moore; Katia Manova; Cristina R Antonescu; Peter Besmer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-16       Impact factor: 11.205

10.  Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296.

Authors:  Shuji Ueda; Hirokazu Ikeda; Masao Mizuki; Jun Ishiko; Itaru Matsumura; Hirokazu Tanaka; Hirohiko Shibayama; Hiroyuki Sugahara; Emi Takai; Xian Zhang; Takashi Machii; Yuzuru Kanakura
Journal:  Int J Hematol       Date:  2002-12       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.